Navigation Links
New form of intravenous iron treats anemia in chronic kidney disease patients on dialysis

Ferumoxytol, a novel intravenous form of iron that permits rapid administration of large doses, has been shown to be effective for treating iron deficiency in chronic kidney disease (CKD) patients on dialysis, according to a clinical trial appearing in the February 2009 issue of the Clinical Journal of the American Society Nephrology (CJASN). The results indicate that this new agent may become an important treatment option for CKD patients.

Because blood is removed during dialysis, CKD patients undergoing this treatment often have anemia, or low red blood cell counts. These patients also are often iron deficient and must receive supplemental iron. While current treatment guidelines recommend intravenous iron for these patients, many clinicians believe that oral iron is much safer than intravenous iron, which has been associated with hypersensitivity reactions and low blood pressure. However, a new form of intravenous iron, ferumoxytol, may be a safe and effective alternative to other forms of iron therapy. Ferumoxytol appears to contain less free iron and be less immunogenic than other intravenous forms of iron.

Robert Provenzano, MD, FASN, of St. John Hospital and Medical Center in Detroit, MI, and his colleagues conducted a phase three clinical trial that compared ferumoxytol with oral iron. The trial enrolled 230 anemic patients with late stage CKD who were on dialysis. Patients received either two injections of 510 mg ferumoxytol within seven days or 200 mg oral iron daily for 21 days. The investigators measured the change in hemoglobin in patients from the start of the trial to day 35.

The two injections of ferumoxytol led to significantly greater hemoglobin increases compared with oral iron supplementation. Specifically, ferumoxytol caused an average of 1.02 g/dL increase in hemoglobin at day 35 compared with 0.46 g/dL with oral iron. Also, twice as many ferumoxytol-treated patients than oral irontreated patients achieved a ≥1 g/dL hemoglobin increase at day 35 (49.0% vs 25.0%). In addition, ferumoxytol was found to be well tolerated relative to oral iron, with 8.2% of ferumoxytol-treated subjects and 15.9% of oral iron-treated subjects experiencing adverse reactions considered by the investigator to be related to study treatment.

"Ferumoxytol administered as two rapid intravenous injections of 510 mg each within a week's time, led to significantly greater hemoglobin increases and was well tolerated as compared with oral iron," said Dr. Provenzano. He added that the study's findings also provide insight into factors that affect greater hemoglobin response to intravenous iron treatment, which makes ferumoxytol a potentially attractive treatment option for anemic hemodialysis patients."

AMAG Pharmaceuticals, Inc. funded the study, and its employees identified study sites, monitored the study to ensure adherence to Good Clinical Practice, and performed data analyses according to the predefined statistical analysis plan. Dr. Provenzano is a member of the Clinical Studies Steering Committee of AMAG Pharmaceuticals, Inc. Authors Brian Pereira, MD and Louis Brenner, MD are employees of AMAG Pharmaceuticals, Inc. Brigitte Schiller, MD and Daniel Coyne, MD were ferumoxytol study investigators. An abstract of some of these findings was submitted to the October 2007 ASN Meeting.


Contact: Shari Leventhal
American Society of Nephrology

Related medicine news :

1. Most Important Factors Driving Usage of Antibiotics in the ICU Setting are Availability in Intravenous Formulation, Activity Against Key Gram Negative Pathogens, Drug Interactions and Bactericidal Activity
2. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
3. FDA Clears MDN-CGS(R) Intravenous Insulin Dosing Software
4. Lifeline Vascular Access Treats a Quarter Million Patients
5. Cancer drug effectively treats transplant rejections
6. Holiday Treats and Decorations Can Be a Deadly Combination for Pets
7. Slippery slope: 1 tiny truffle can trigger desire for more treats
8. Dogs Get Petty About Treats
9. Sealing off portion of intestinal lining treats obesity, resolves diabetes in animal model
10. Tips for Maintaining Your Physique While Enjoying Your Favorite Treats
11. Orthodontists Offer Sweet Incentives for Tricky Halloween Treats
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb ... the leading plastic surgery practices in Florida, is proud to announce that Dr. ... surgical innovations giant Ethicon Inc., a Johnson & Johnson Company. , Ethicon is ...
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of an Investigational New Drug ... so important to this key industry segment, Regis Technologies has decided to sponsor and ... 4th at 11am EST. , Federal law does not allow new drugs to cross ...
(Date:11/30/2015)... ... November 30, 2015 , ... Healthjump, Inc. ... Inc., a Healthcare IT consulting, development and support company. The purchase will expand ... available within DataTrade to extend the services currently provided by Healthjump. ...
(Date:11/30/2015)... ... November 30, 2015 , ... GKhair & Tibolli team members and artists were ... held on November 8th and 9th at the Puerto Rico Convention Center, San Juan ... beauticians and top of the line fashion journalists. The San Juan Beauty Show carries ...
(Date:11/30/2015)... ... 2015 , ... Innovaacom, a leading provider of medical education ... of educational needs for pharmacists worldwide. The poll of pharmacists in Europe, Asia, ... online and face-to-face education for pharmacists who are fast becoming the new “gatekeepers” ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... HANOVER, N.J. , Nov. 30, 2015  Novartis ... portfolio at the 57 th American Society of ... leukemias, lymphomas and myelomas as well as supportive care, ... in addition to personalized cell therapies. The ASH Annual ... Orlando, Florida . Novartis Oncology . ...
(Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
(Date:11/30/2015)... 2015 Elbit Imaging Ltd. (TASE, ... today that it was informed by InSightec Ltd. ("InSightec"), that ... has approved its Exablate Neuro system to treat movement, ... --> Insightec,s Exablate Neuro platform is transforming ... two technologies: Focused Ultrasound, which is used to lesion ...
Breaking Medicine Technology: